1	Insights on Genetic and Environmental Factors in Parkinson's
2	Disease from a regional Swedish Case-Control Cohort
3	
4	
5	Kajsa Brolin <sup>1*</sup> , Sara Bandres-Ciga <sup>2</sup> , Cornelis Blauwendraat <sup>2</sup> , Håkan Widner <sup>3.4</sup> , Per Odin <sup>3,4</sup> ,
6	Oskar Hansson <sup>5,6</sup> , Andreas Puschmann <sup>3,4</sup> , Maria Swanberg <sup>1</sup>
7	
8	<sup>1</sup> Lund University, Translational Neurogenetics Unit, Department of Experimental Medical
9	Science, Lund, Sweden, <sup>2</sup> Laboratory of Neurogenetics, National Institute on Aging, National
10	Institutes of Health, Bethesda, MD, USA, <sup>3</sup> Lund University, Department of Clinical Sciences
11	Lund, Neurology, Sweden, <sup>4</sup> Department of Neurology, Skåne University Hospital, Sweden,
12	<sup>5</sup> Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University,
13	Sweden, <sup>6</sup> Memory Clinic, Skåne University Hospital, Malmö, Sweden
14	
15	*Corresponding author: Kajsa Brolin, kajsa.brolin@med.lu.se, Translational Neurogenetics,
16	BMC A10, 221 84, Lund, Sweden
17	
18	Abstract
19	BACKGROUND: Risk factors for Parkinson's disease (PD) can be more or less relevant to a
20	population due to population-specific genetic architecture, local lifestyle habits, and
21	environmental exposures. Therefore, it is essential to study PD at a local, regional, and
22	continental scale in order to increase the knowledge on disease etiology.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

<u>OBJECTIVE:</u> We aimed to investigate the contribution of genetic and environmental factors
 to PD in a new Swedish case-control cohort.

METHODS: PD patients (n=929) and matched population-based controls (n=935) from the southernmost county in Sweden were included in the cohort. Information on environmental exposures was obtained using questionnaires at inclusion. Genetic analyses included a genomewide association study (GWAS), haplotype assessment, and a risk profile analysis using cumulative genetic risk scores.

30 <u>RESULTS:</u> The cohort is a representative PD case-control cohort (64% men, mean age at 31 diagnosis=67 years, median Hoehn and Yahr score=2.0), in which previously reported 32 associations between PD and environmental factors, such as tobacco, could be confirmed. We 33 describe the first GWAS of PD solely composed of PD patients from Sweden, and confirm 34 associations to well-established risk alleles in *SNCA*. In addition, we nominate an unconfirmed 35 and potentially population-specific genome-wide significant association in the *PLPP4* locus 36 (rs12771445).

37 <u>CONCLUSIONS:</u> This work provides an in-depth description of a new PD case-control cohort
 38 from southern Sweden, giving insights into environmental and genetic risk factors of PD in the
 39 Swedish population.

40

41

42 MESH keywords:

43 Parkinson Disease, Sweden, Case-Control Studies, Risk Factors, Genome-Wide Association
44 Study, Haplotypes

45

46

## 48 Introduction

49

50 Parkinson's disease (PD) has been reported to be the fastest growing neurological disorder 51 worldwide in terms of prevalence, disability, and deaths [1, 2]. Currently available treatments 52 only address symptoms, and the burden of PD will increase substantially if no disease-53 modifying therapeutic is developed.

54

55 PD can be categorized into monogenic and idiopathic (multifactorial) based on the contribution 56 of genetics to disease risk. In monogenic PD, rare DNA variants with large effect sizes but 57 varying penetrance cause the disease [3]. Although such variants in SNCA, LRRK2, VPS35, 58 PRKN, PINK1, GBA, and DJ-1 [4-9] contribute to a small proportion of cases, these genes have 59 provided valuable insight into the molecular mechanisms underlying PD etiology and 60 pathogenesis, as well as an overlapping etiology between monogenic and idiopathic PD. 61 Missense mutations and copy number variants (CNVs) of SNCA, encoding a-synuclein, have 62 been identified to cause monogenic PD, whereas common SNCA variants have been associated 63 with an increased risk of idiopathic PD [5]. In idiopathic PD, accounting for more than 95% of 64 all PD cases, variants with relatively small effect sizes in combination with environmental 65 exposures influence an individual's disease risk [10, 11]. The latest large-scale genome-wide 66 association study (GWAS) meta-analysis identified 90 risk loci associated with PD in 67 individuals of European ancestry [12]. These variants were estimated to explain 16-36% of the 68 heritable PD risk, indicating that many genetic risk factors for PD remain to be discovered [12]. 69 Additionally, two new risk loci have been reported to be associated with PD risk in the Asian 70 population [13].

Larger sample sizes in GWAS could pave the way for the discovery of additional risk variants and increase the proportion of explained heritability [14, 15]. However, it has also been suggested that the "missing heritability" could be explained by the presence of gene-gene and gene-environment interactions [14]. Commonly reported environmental risk factors for PD include smoking and exposure to pesticides, two exposures that can vary a lot between population. Further understanding environmental risk factors for PD in different populations are hence of great importance to further elucidate the pathogenesis of the disease [10, 16, 17].

There is a strong population bias towards individuals of European ancestry in genetic research of human diseases [18, 19], but initiatives are taken to study PD genetic risk in other populations [20, 21]. In addition to the need of a widened scope of PD genetic research on a global level, narrowed studies are also of interest, since heterogeneity across cohorts from different countries or regions may mask genetic associations specific to sub-population [22].

85

86 The Swedish population has not yet been represented in PD GWAS meta-analyses or 87 population-specific GWAS aside from a PD GWAS performed on a mixed Scandinavian 88 population from Norway and Sweden [23]. The Swedish population has been reported to be 89 genetically similar to the nearby population of Norway [24, 25]. However, it has also been 90 reported that Swedish genomes contain a substantial amount of genetic variation and genetic 91 variants that are not represented in other European populations [26], and that there is a large 92 genetic difference even within the Swedish population, particularly between the south and 93 north of Sweden [24, 26]. This highlights the importance of analyzing different European 94 populations, and emphasize the importance of regional matching of cases and controls in 95 GWAS [24, 27].

97 Here, we provide a comprehensive description of a novel, well-defined, and matched PD case-98 control cohort from southern Sweden in which we describe, to our knowledge, the first GWAS 99 of PD composed solely of individuals from Sweden. This study provides insights into 100 environmental and genetic risk factors of PD in the Swedish population and will contribute to 101 the understanding of population-specific environmental and genetic risk in PD.

102

## 103 Materials and Methods

104

105 <u>Ethical consent</u>

Ethical permission for the MultiPark's biobank sample collection (MPBC) was approved by
the regional ethics review board of Lund (2013/509). All participants gave informed written
consent at study enrollment.

109

### 110 Patient and population-based control inclusion

111 Individuals primarily diagnosed with PD (International Classification of Disease, tenth 112 revision (ICD-10-SE) code G20.9) in the southernmost province of Sweden, Scania, were assessed for eligibility (Figure S1). Inclusion criteria were a PD diagnosis and the ability to 113 114 visit one of the clinics for sampling. In total, 2,119 PD patients were invited to participate 115 between November 2014 and July 2017, whereof 1,011 were included (inclusion rate 48.3%). 116 For each patient, population-based controls matched by date of birth, sex, and residential area 117 were randomly selected from the Swedish Population Register and invited between March 118 2015 and April 2018. A total of 1,001 individuals consented and completed data collection 119 (inclusion rate 18.5%). Exclusion criteria were a PD diagnosis and the inability to visit a center 120 for sampling. Out of the completed controls, 953 were unique matchings, resulting in a matched 121 control for 953 PD patients (94.3%). All analyses were performed in a set of 929 patients and

935 controls passing all quality control (QC) steps unless stated otherwise. A flowchartdetailing the study participant inclusion process can be found in Figure S2.

124

#### 125 Sample and data collection, storage, and management

126 Blood samples were handled by the Clinical Chemistry Unit at the University Hospital in Scania (SUS) and stored at -80°C within a central biobanking facility (Biobank Syd: BD47). 127 128 Whole blood was collected in EDTA-tubes (Becton Dickinson (BD) Vacutainer®, New Jersey, 129 US) for DNA extraction. Additional samples were collected in PAXgene blood RNA tubes 130 (QIAGEN®, Hilden, Germany), EDTA-tubes (BD Vacutainer®), sodium-heparin tubes (BD Vacutainer®, New Jersey, US) and a serum-separating tube (BD Vacutainer® SST<sup>™</sup>, New 131 Jersey, US) to enable future studies of RNA and biomarkers in PD. When difficulties emerged 132 133 during blood sample collection, EDTA-tubes for DNA extraction were prioritized. Serum and 134 plasma samples are stored at -80°C in a 96-well format of 200 µl aliquots.

135

136 All participants filled in questionnaires covering basic demographic data, lifestyle habits, 137 family history of PD, comorbid diseases, environmental exposures, medications, health status, 138 and perceived motor- and non-motor symptoms. Data from questionnaires was manually 139 entered into the web-based application REDCap [28]. Additional data for the PD rating tools 140 Hoehn and Yahr (H&Y), Clinical Impression of Severity Index - Parkinson's Disease (CISI-141 PD), and Parkinson's Disease Questionnaire - 8 (PDQ-8), as well as information on age at 142 diagnosis (AAD) retrieved from the Swedish Parkinson's registry was 143 (https://www.neuroreg.se/parkinsons-sjukdom/).

- 144
- 145
- 146

#### 147 Statistical analyses of epidemiological data

Epidemiologic data was analyzed using R version 4.0.0 [29]. Demographic characteristics were 148 149 summarized as frequency and percentage for categorical variables. For continuous variables, 150 mean and standard deviation (SD) were used for variables displaying normal distribution 151 whereas median and interquartile range was reported for non-normally distributed variables. 152 The range for continuous variables was used to demonstrate the heterogeneity in the cohort. 153 Body mass index (BMI) was calculated as weight (kg)/height (m)<sup>2</sup>. For quality-of-life assessment, EuroQol five-dimension-3-level (EQ-5D-3L) was used, covering mobility, self-154 155 care, usual activities, pain/discomfort, and anxiety/depression. Time trade-off (TTO) and the 156 visual analogue scale (VAS) index were calculated using scale value sets for Sweden [30]. In TTO valuation, individuals were asked to indicate how many years in full health that would be 157 158 of equal value to 10 years in their current health state (divided by 10). Full health hence 159 corresponds to 10 years/10=1. In VAS valuation, respondents rated their overall health between 160 0 (worst imaginable health) and 100 (best imaginable health) [31]. Additionally, the occurrence 161 of PD symptoms at study inclusion were compared between the patients and controls using 162 Pearson's chi square test with a Bonferroni corrected threshold for statistical significance of 163 p=0.001.

164

165 To test for associations between potential risk factors and PD status, both unadjusted and 166 multivariate logistic regression analyses were used. Risk factors were selected based on meta-167 analysis literature reviews [16, 17]. Due to the cross-sectional case-control study design, we 168 selected variables from the questionnaire related to past exposures, excluding variables related 169 to exposures at time or near time of inclusion. Directed acyclic graphs (DAGs) were made for 170 all exposures of interest using the R package 'dagitty' to help identify confounding variables 171 to adjust for in the multivariate analyses (Figure S3) [32]. Confounding pathways with the least

amount of missing data were prioritized and complete-case analyses were run. Odds ratios(OR), and 95% confidence intervals (CI) were estimated and plotted in a forest plot.

174

175 We further evaluated variables for BMI and comorbidities at inclusion, along with alcohol and 176 red wine consumption and physical exercise the year prior to inclusion, and ibuprofen use the past two weeks prior to inclusion, using logistic regression analyses, adjusting for age and sex. 177 178 We acknowledge the risk of confounding factors but the interest was solely to perform 179 observational analyses. Complete-case analyses were run and ORs and 95% CI were estimated 180 and plotted in a forest plot. A total of 35 comorbidities were not evaluated for association due 181 to either too few study participants reporting a certain diagnosis or a lack of difference between 182 the occurrence of the diagnosis between the patient and control group.

183

#### 184 DNA extraction and Genotyping

DNA extraction was done from whole blood at BD47 and at LGC Biosearch Technologies (UK, GEN-9300-120). LGC Biosearch Technologies (Germany) also performed genotyping and subsequent "Basic BioIT" with technical QC and genotype clustering. The no-call GenCall threshold was set to the standard score cutoff for Infinium data of 0.15. Matched case-control samples were genotyped using the Infinium Global Screening Array-24 v.2.0 with the Multi-Disease drop in panel v.2.0 (GSAMD-24v2.0) containing 712,189 variants annotated to the Genome Reference Consortium Human Build 37 (GRCh37).

192

#### 193 <u>Genotype quality control and Imputation</u>

194 QC analysis was performed in PLINK 1.9 [33, 34]. Samples were excluded if the call rate was

195 <95%, if excess heterozygosity was detected (estimated by a F statistic >0.15 or <-0.15), or if

196 the genetic sex (determined from X-chromosome heterogeneity) differed from the reported sex.

197 Principal component analysis (PCA) was used to identify and exclude ancestry outliers. For 198 this, the genotype data was merged with the HapMap phase 3 data set [35], and samples were 199 determined as having European ancestry if they clustered 6 SD (+/-) around the combined 200 population mean of the populations: Utah residents with Northern and Western European 201 ancestry (CEU) and Toscani in Italia (TSI) (Figure S4). Samples from closely related 202 individuals, defined as sharing more than 12.5% of alleles, were also excluded. Following 203 sample exclusion, 929 patients and 935 controls remained. Variant level QC was subsequently done, excluding SNPs with a missingness rate >5%, Hardy-Weinberg equilibrium p-value <1E-204 205 4, or minor allele frequency (MAF) <1%. SNPs with differences in genotyping rate for patients 206 and controls, and genotypes missing by haplotype, were also excluded for p-value <1E-4. SNPs 207 passing QC were 505,005 with a total genotyping rate of 99.9%. Genomic imputation was 208 performed on the Michigan Imputation Server [36] using the Minimac4 imputation software, 209 Eagle v2.4 for phasing [37], and the Haplotype Reference Consortium (HRC) r1.1 2016 210 European population as the reference population (http://www.haplotype-reference-211 consortium.org/) [38]. Post-imputation OC was performed, and variants with MAF<5% and/or 212 poor imputation quality, set as Rsq <0.3, were excluded. The number of imputed variants after 213 filtering was 5,445,841.

214

### 215 <u>Power calculation for GWAS analyses</u>

GWAS power calculation was performed using the online Genetic Association Study (GAS) Power Calculator (http://csg.sph.umich.edu/abecasis/gas\_power\_calculator/). In order to reach 80% power at a GWAS-significance level (alpha=5E-08) with a disease prevalence in the general Swedish population of 0.2%, an allele frequency of >20% and an OR>1.7 would be needed.

#### 222 Genome wide association study (GWAS) vs PD risk and age at diagnosis (AAD)

A GWAS for PD risk was performed in a logistic regression model adjusted for sex, age (at 223 224 study inclusion), and the first 5 principal components (PCs). The number of PCs used in the 225 analyses was determined by a scree plot (Figure S5). A linear regression model was used to 226 investigate the impact of genetic variation on the AAD, adjusted for sex and PC1-5. Data on 227 AAD was available for 792 of the 929 PD patients (85.3%). Summary statistics was generated 228 using RVTESTS (version 2.1.0) [39]. Quantile-quantile (QQ)-plots and Manhattan plots were 229 generated in R, version 4.0.0 [29]. Subsequently, regions of interest were visualized using 230 summary statistics data in the LocalZoom tool (https://my.locuszoom.org) with a flanking size 231 of 100 kb from the gene of interest.

232

#### 233 Haplotype analysis of PLPP4

234 Genotyped variants in the *PLPP4* region with a window of  $\pm 100$  kb (*PLPP4* coordinates 235 on GRCh37; chr10:122216466-122349376, UCSC) was extracted and annotated using 236 ANNOVAR [40]. Haplotype blocks in the region were estimated in PLINK v1.9 using the 237 default parameters wherein pairwise LD was calculated for variants within 500 kb [33, 34]. 238 PLINK v1.9 estimates haplotype blocks following the default procedure in Haploview [41, 42]. 239 Association between haplotype blocks in *PLPP4* and PD status was analyzed with haplo.stats 240 in R. The regression analyses were adjusted for age, sex, and PC1-5, and additionally for 241 tobacco use. The adjustment for tobacco use was done because of a report of PLPP4 being 242 associated with smoking cessation [43], and multiple reports of smoking being associated with 243 PD. To assimilate the effect of other nicotine products, such as snus (moist tobacco, commonly 244 consumed in Sweden), the variable "Tobacco" was used. Only haplotypes with a carrier frequency of >1% were included in the analysis. A Bonferroni corrected threshold for statistical 245

significance of p=0.05/16=0.003. was set. The results were visualized using LocusZoom
(https://my.locuszoom.org) and Haploview v4.1 [44].

248

### 249 Analysis of the joint effect of variants in *PLPP4* on PD risk

250 The contribution of rare variants on PD risk was examined by the joint effect of multiple 251 variants in the PLPP4 region. We separately analyzed genotyped and imputed variants with an 252 imputation quality score of Rsq >0.8 for imputed variants. The sequence kernel association test (SKAT) was used since only 2.6% of the variants in PLPP4 are coding variants and the SKAT 253 254 is powerful when a large fraction of variants in a region are noncoding. The test aggregates 255 associations between variants and phenotype and allows for variant interactions [45]. The 256 analyses were performed in RVTESTS (version 2.1.0) [39] using default parameters and 257 adjusting for age, sex and PC1-5. The test was performed both for all available variants as well 258 as in only coding variants with two different maximum MAF thresholds of <1% and <5%. To 259 adjust for multiple comparisons, Bonferroni corrected p-value thresholds was applied for all 260 analyses.

261

## 262 <u>Risk profile analysis</u>

263 A risk profile analysis for PD and AAD was performed using the imputed data passing QC. A 264 cumulative genetic risk score (GRS) was calculated in PLINK v1.9 using publicly available 265 effect estimates (beta coefficients) of 90 SNPs associated with PD in the largest published 266 meta-analysis of PD GWAS to date [12]. For each SNPs, the allele dosage was multiplied by the beta coefficient, giving a greater weight to alleles with higher risk estimates. Risk allele 267 268 dosage was then summed across all variants to generate a GRS for each study participant. 269 Subsequently, the GRSs were standardized to Z-scores using the control group as the reference 270 group for PD status and the patient group for the AAD analysis. Following standardization, a

271	Z score of 1 can be interpreted to be equivalent to one SD increase in the GRS from the
272	reference group GRS mean. The study participants were divided into quartiles based on their
273	GRS, and logistic regression analysis was performed to investigate associations and estimate
274	the OR between PD status and quartile group. Covariates were selected from a previously
275	published PD classification [46] and included PD family history (yes/no), age at inclusion, sex,
276	and additionally PC1-5. For the risk profile analysis for AAD, a linear regression model was
277	used, adjusted for sex, PD family history, and PC1-5. Plots were generated in R, version 4.0.0
278	[29].
279	
280	Code for all analyses will be available at https://github.com/KajBro/MPBC, GWAS summary

- 281 statistics will be available <u>online</u>.
- 282
- 283 Results
- 284

## 285 Characteristics of the MPBC cohort

286 Demographics and characteristics of the MPBC cohort are summarized in Table 1. An expected 287 male predominance was observed with a sex ratio of 2:1. Case-control matching was successful 288 for year of birth and sex, with average birth year 1944 and 36% women in both groups. A one-289 year difference for the average age at inclusion was observed between patients (71 years) and 290 controls (72 years) due to control matching occurring after patient inclusion. Swedish ancestry 291 (defined as self-reporting that both parents were born in Sweden) was similar in patients and 292 controls (87.9% vs 86.1%). Similar distributions for highest completed education and marital 293 status were also seen. According to self-reported information on health status using the EQ-5D-3L instrument [30], patients had an index of 0.8 on the TTO scale compared to 0.9 for the 294 295 controls. The patients also rated their own overall health lower than the controls on the VAS

index scale (index 68.9±16.8 vs 82.0±9.7, Table 1). As a reference, the general Swedish
population has an estimated mean TTO index of 0.9 and a VAS index of 79.5 [30]. As expected,
all PD symptoms were more common in the patient group than the control group (Table S3).
The most common self-reported motor-symptoms were muscle stiffness (72.7%) followed by
slowness of movements (72.4%). The most commonly reported non-motor symptom for both
patients and controls was nocturia (71.6% vs 58.4%).

302

303 We further evaluated the health status and AAD among male and female PD patients (Table 304 2). Median AAD was identical for both sexes (67.0 years), although with a wide range (men 305 29.0-84.0 years, women 35.0-89.0 years). The median time since diagnosis at inclusion was 306 4.0 years for both sexes and varied from diagnosis the same year to 36.0 years for men and 307 33.0 years for women. Health status at the time of inclusion was evaluated using the H&Y 308 scale, CISI-PD, and PDQ-8. Both sexes had a median of 2.0 on the H&Y, corresponding to 309 bilateral involvement without impairment of balance. Similar total score values were reported 310 by men and women on the CISI-PD scale (median 5.0, range 0-24). Women had a slightly 311 higher median PDQ-8 total score compared to men (7.0 vs 6.0 out of 32).

312

#### 313 Epidemiological characteristics of PD in Sweden

We further set out to evaluate previously confirmed risk factors for PD in a regional, Swedish context (Figure 1, Table S1). A positive family history (at least one relative diagnosed with PD) was overrepresented among PD patients compared to controls (20% vs 11%). Consequently, having a relative diagnosed with PD doubled the risk of having PD (OR=2.00, 95% CI 1.51-2.67). An association between pesticide exposure and PD was confirmed at an OR of 2.26 (95% CI 1.39-3.72). A significant association was also seen between PD and a history of head trauma (OR=1.30, 95% CI 1.08-1.58). However, no association between loss

321 of consciousness and PD was observed among study participants who reported a history of head trauma. A slightly higher OR was seen for a higher BMI at the age of 20 years (1.05, 95%) 322 323 CI 1.01-1.09), indicating that a one unit increase in BMI increased the risk of having PD by 324 5%. However, no difference was observed for the highest reported BMI. We observed an 325 inverse association between having ever smoked and PD, but the association was not 326 statistically significant after adjustment for confounders (ever- vs never-smoking OR=0.82, 327 95% CI 0.67-1.01). A statistically significant inverse association between snus and PD was observed also after adjusting for confounders (OR=0.53, 95% CI 0.38-0.73). An inverse 328 329 association was also observed for the combined effect of tobacco products on PD (adjusted 330 OR=0.72, 95% CI 0.59-0.88). Moreover, a trend of lower OR for PD with increasing amount of coffee drinking at all investigated age groups was observed, where drinking >5 cups of 331 332 coffee per day was inversely associated with PD (OR 0.36-0.52, 95% CI 0.18-0.86).

333

334 Additionally, variables related to exposure/use within the past year were examined to describe 335 potential differences between the age- and sex-matched groups at inclusion (Figure 2, Table 336 S2; Table S3). The patients consumed less alcohol and engaged in less physical activity both 337 in regard to level of physical activity (regular activity level vs nothing OR=0.26, 95% CI 0.18-338 0.38) and hours per week (≥5 hours/week vs nothing, OR=0.21, 95% CI 0.13-0.33). No 339 significant association between PD and BMI at inclusion was observed (OR=0.99, 95% CI 340 0.96-1.00). For comorbidities, statistically significant inverse associations between PD and a 341 diagnosis of hyperlipidemia (OR=0.51, 95% CI 0.40-0.64), hypertension (OR=0.57, 95% CI 342 0.47-0.69), and osteoarthritis (OR=0.66, 95% CI 0.53-0.82) were seen. A significant 343 association with PD was observed for a diagnosis of depression (OR=1.89, 95% CI 1.39-2.59), 344 back pain (OR=1.56, 95% CI 1.15-2.13), and bowel problems, where bowel problems (defined 345 as having constipation or diarrhea that required treatment on a regular basis) almost quadrupled

the likelihood of having PD (OR=3.93, 95% CI 2.66-5.97). We observed an OR of 0.53 (95% CI 0.41-0.68) for the use of ibuprofen <2 times/week compared to never. However, the association was lost for ibuprofen use  $\geq 2$  times/week. No associations were observed for the use of other nonsteroidal anti-inflammatory drugs (NSAIDs), such as diclofenac or naproxen (data not shown).

351

#### 352 <u>GWAS of PD risk nominated a novel genome-wide significant variant in the PLPP4 locus</u>

353 The variant rs356182 in SNCA was reported in the latest GWAS meta-analysis as one of the 354 90 risk loci associated with PD in a cohort of European ancestry [12]. In our GWA analysis for PD risk, this and another three variants in the SNCA locus were observed at low p-values 355 356 (rs356182, beta=-0.38, SE=0.07, p=5.64E-08; rs356203, beta=-0.36, SE=0.07, p=1.27E-07; rs356220, beta=0.36, SE=0.07, p=1.39E-07; rs356219, beta=-0.36, SE=0.07, p=2.32E-07), but 357 358 none reached genome-wide significance (Table S4). In addition to the SNCA variants, we found 359 associations for 23 of the 90 previously reported PD risk loci in this Swedish cohort at an 360 uncorrected p-value of 0.05 (Table S5). Results from PCA showing the population structure as 361 compared to the HapMap3 reference populations, revealed that this Swedish cohort cluster near 362 the other European population but the centers of the clusters differ slightly, indicating 363 differences in population structures that could result in population-specific risk alleles (Figure 364 S6). The GWA analysis also revealed a novel genome-wide significant association signal in 365 the PLPP4 locus, rs12771445 (10:122318147, beta=-0.44, SE=0.07, p=1.30E-08), as being 366 associated with PD in this Swedish cohort (Figure 3, Table S4). This association has, to our 367 knowledge, not been reported in any other cohort (Table S4) [12]. The significant variant was 368 an intron variant in the gene Phospholipid Phosphatase 4 (PLPP4) and was imputed with Rsq=0.99 and MAF=0.31 (Table S4). The MAF is similar to the value observed in the Swedish 369 370 reference population, SweGen, of 0.32 [26]. The estimated MAF was 0.27 in the patient group

371 and 0.36 in the control group, indicating a potential protective effect of the minor allele (T) with an OR of 0.64. To further display the association signals relative to genomic position and 372 373 local LD, locus zoom plots for PLPP4 rs12771445 and SNCA rs356182 were produced (Figure 374 4 and Figure S10). Variants in SNCA have been reported to also be associated with PD AAO [47]. We performed a GWA for the related variable AAD of PD in the cohort. However, we 375 376 did not detect any genome-wide statistically significant associations and could not replicate 377 previous reported variants associated with PD AAO at low p-values, likely due to smaller 378 sample size (792 vs 28,568) [47], and limited statistical power (Figure S11 and S12).

379

In order to analyze more genetic variants, imputation was done using the beta-version of the TOPMed Imputation Reference panel [48]. Using the same post-imputation QC, 6,214,098 variants were generated and analyzed in a GWAS for PD risk (Figure S8 and S9). Two variants passed genome-wide significance, rs12772937 (chr10:122318146, beta=-0.40, SE=0.07, p=2.48E-08) and our previously identified rs12771445 (10:122318147, beta=-0.40, SE=0.07, p=2.48E-08). Since the TOPMed panel was still in the beta stage as of our analysis, we continued using the data imputed with the HRC version r1.1 2016 panel.

387

#### 388 Haplotype analysis of *PLPP4*

Because of the identification of the novel genome-wide signal (rs12771445) associated with PD in this cohort, we further looked at haplotypes among the genotyped variants in the nearest gene, *PLPP4* ( $\pm$  100 kb), to capture the genetic variance in the region. We identified 92 genotyped variants passing QC in the region, where 32 were in *PLPP4*, all intron variants. The median GenCall scores of these variants was 0.87 (IQR: 0.83–0.91) (Figure S13). A total of 45 different haplotypes in 12 different blocks (H1-H12) in the region was identified (Table 3, Figure S14). Statistically significant association with PD was observed for a haplotype in one

block (H6) (p=2.45E-05), both before and after adjustment. The haplotype block spanned over
41.9 kB (chr10:122302038-122343950) and consisted of five genetic variants and six different
haplotypes. The rs978854(G)-rs7910507(G)-rs10886711(G)-rs11199417(G)-rs10886717(A)
haplotype was statistically significantly inversely associated with PD at an OR of 0.69 (95%
CI 0.59-0.82, p=2.54E-05) and with a MAF=0.24 for patients and 0.30 for controls.

401

#### 402 <u>Analysis of the joint effect of variants in *PLPP4* on PD risk</u>

We further evaluated the joint effect of more rare variants (MAF <5%) in PLPP4 on PD risk 403 404 using both genotyped and imputed data. No coding variants in the gene were identified in the 405 genotyped data and only one was identified in the imputed data (Table 5). When focusing on 406 all variants, an association in the genotyped data at MAF<5% was observed (p=0.002), passing 407 Bonferroni correction. A trend of a potential joint effect of variants with a MAF<5% was still 408 observed in the imputed data (p=0.005). However, it did not reach multiple testing corrections 409 (p-value threshold=0.05/628=7.96E-05). Only one variant with MAF<1% was present in the 410 genotyped data and no statistically significant association was observed for variants with 411 MAF<1% in either the genotyped or the imputed data.

412

#### 413 <u>Genetic PD risk profile</u>

The PD risk profile analysis showed that the Z-standardized GRS from Nalls et al was associated with PD status also in this Swedish case-control cohort [12]. For each SD increase from the reference mean value, the OR increased by 1.8 (beta=0.59, SE=0.05, p<2.22E-16) (Figure 5). Study participants in the highest GRS quartile were estimated to be 4.7 times more likely to have PD compared to the participants in the lowest quartile using an adjusted model. There was also an inverse association between the GRS and AAD, where one SD increase in

the Z-standardized GRS was associated with approximately one-year earlier AAD (beta=-0.97,
SE=0.36, p=0.007, adjusted r<sup>2</sup>=0.011).

422

## 423 Discussion

424

This study is, to our knowledge, the largest case-control study of PD performed in a Swedish cohort. The study includes a well-defined recruitment of matched study participants from a specific region in southern Sweden. Multiple previously reported environmental and genetic risk factors were confirmed to affect PD risk. Interestingly, a novel genome-wide significant association with PD risk at the *PLPP4* locus was observed, both in the GWA and the haplotype analysis but further validation of the nominated variant is needed.

431

432 The MPBC cohort demonstrates similar characteristics compared to other PD cohorts. At 433 inclusion, the patients had a relatively short disease duration (average 4 years), which was 434 reflected in the PD rating scales with an average score of 2 on the H&Y scale and low scores on the CISI-PD and PDQ-8 scales. This can be explained by the study inclusion design where 435 436 patients with advanced PD, who could not visit a neurology clinic, were not eligible. For self-437 reported PD symptoms, hypokinesia/bradykinesia was most common, occurring in 72% of the 438 patients. Non-motor symptoms occurring at later stages of the disease, such as delusions and 439 hallucinations were less frequent (6.0% and 16.8%), also highlighting the lower number of 440 patients with advanced PD in the cohort [49]. The lack of an association between BMI at 441 inclusion and PD further highlight this. Weight loss has frequently been observed in PD 442 patients as a consequence of reduced energy intake in combination with an increased energy expenditure due e.g. levodopa-induced dyskinesia [50]. It has been estimated that PD patients 443 444 lose 3.5 kg every eight years post-diagnosis and that levodopa-induced dyskinesia commonly

445 develops after 3-5 years [50, 51]. Approximately 92% of the patients in the cohort reported446 using levodopa therapy.

447

448 Several previously reported environmental PD risk factors could be confirmed in this Swedish 449 cohort. Among those, an association between pesticide exposure and PD was observe, where 450 exposure to pesticides more than doubled the risk of having PD. The number of participants 451 exposed to pesticides was overrepresented among those who had reported farming and well 452 water consumption. However, no statistically significant association was observed between 453 farming or well water and PD in the cohort. Several pesticides have been reported to be linked 454 to PD, including paraquat, glyphosate, and pyrethroids [52]. Paraquat was banned in Sweden 455 in 1983 while glyphosates and pyrethroids are still used [53]. However, further actions need to 456 be taken to investigate which chemicals stand behind the observed association.

457

458 Having a relative with a PD diagnosis doubled the risk of having PD in the cohort. Among the 459 20% of patients that reported a positive family history, 8.9% had a first-degree relative with 460 PD. Other studies report similar numbers with 15-25% of PD patients having a positive family 461 history and 10-25% having a first-degree relative with PD [54]. It has been suggested that the 462 risk of PD increases shortly after a traumatic brain injury (TBI) and that a history of 463 concussions results in a higher risk of PD [55, 56]. We also observed a statistically significant 464 association between a history of head trauma and PD, but whether the association is causative 465 or a consequence of prodromal PD remains to be determined. Among participants reporting head trauma, no association was observed between PD and loss of consciousness. 466

467

The inverse association between smoking and PD is well-known and has been reported in numerous studies [17]. This was initially replicated in the cohort, but no longer statistically

470 significant after adjustment for confounders, which could be due to the common co-occurrence of smoking and the use of snus. Interestingly though, a strong inverse association between the 471 472 Swedish moist tobacco snus and PD was observed also after adjustment. The amount of 473 nicotine reaching the blood when using snus is equivalent of that of cigarette smoking, and the 474 observation reduces the number of candidate compounds underlying the inverse association 475 between smoking and PD [57, 58]. It has previously been reported that non-smoking, snus-476 using Swedish men had 60% lower risk of PD compared to men who had never used snus [58]. 477 Snus is more frequently used than smoking tobacco among men in Sweden, where 18% use 478 snus and 7% smoke on a daily basis. Among Swedish women, 5% use snus and 7% smoke on 479 a daily basis [59]. We investigated the total effect of smoking and snus on PD risk and found 480 a statistically significant inverse association to PD also for the combined variable "Tobacco". 481 Our findings support previous reports and suggest either that components in tobacco leaves 482 influence biological processes underlying PD, or that there is a reverse causation between 483 tobacco use and PD. Nicotine has been suggested to have neuroprotective properties but it also 484 stimulates dopamine release from nigrostriatal dopaminergic terminals. Hence, the lower use 485 of tobacco products could be a consequence of a reduced nicotine-evoked dopamine release 486 among prodromal PD patients [60]. Caffeine has also been reported to have neuroprotective 487 effects in PD animal models, and several epidemiological studies have reported a relationship 488 between increased coffee consumption and decreased risk of developing PD [10]. We could 489 also observe a trend of lower OR for PD with higher coffee consumption in all investigated 490 age groups in this cohort.

491

492 The comorbidities hypertension, hyperlipidemia, and osteoarthritis were inversely associated 493 with PD in the cohort. Autonomic dysfunction can occur in PD, resulting in abnormalities in 494 blood pressure, and orthostatic hypotension is common [61]. In concordance with our results,

495 meta-analysis of PD risk factors has identified an inverse association between hypertension 496 and PD risk [16]. However, this was only observed in case-control studies, indicating that the 497 association might be a consequence of the disease. For hyperlipidemia, there are conflicting 498 reports on the association with PD but a meta-analysis supports an inverse association [62]. It 499 is possible that the use of lipid-lowering drugs (statins) contributes to the observed conflicting 500 associations [63]. The study participants were asked whether they had been diagnosed with 501 hyperlipidemia and, hence, it was likely that they used pharmacological treatments. Statins are 502 the most commonly prescribed lipid-lowering drugs in Sweden, and we cannot rule out that the 503 observed inverse association between PD and hyperlipidemia is a consequence of statin use. 504 Moreover, the PD patients were less likely to have a diagnosis of osteoarthritis (21% patients 505 vs 29% controls). Contrary to our observation, arthritis (no distinction was made between 506 rheumatoid arthritis and osteoarthritis) has been reported to be the most prevalent comorbidity 507 in PD, with almost 47% reported having the condition [64], indicating that our observation 508 could be a consequence of underdiagnosis of osteoarthritis among the PD patients [65]. 509 Furthermore, associations between PD and the comorbidities depression, back pain, and bowel 510 problems were observed. Use of ibuprofen has been reported to be inversely associated with 511 PD in a dose-dependent manner [66]. We observed a reduced PD risk for the use of the NSAID 512 ibuprofen <2 times/week but not for  $\geq$ 2 times/week and a recently published large study do not 513 support any evidence of a decreased PD incidence among NSAID users [67].

514

Here, we describe to our knowledge the first GWAS of PD composed solely of PD patients from Sweden, specifically the southernmost region of Sweden. Although the relatively small sample size is a limitation in this study, issues with population stratification are expected to be lower due to region-specific study recruitment and, potentially, more homogenous ancestry. The observed near genome-wide significance associated variants at the *SNCA* locus indicate

520 that this cohort is a well-designed case-control cohort of PD, and one of the variants was 521 reported among the 90 risk loci in the largest GWAS meta-analysis to date [12]. Another 23 of 522 the 90 risk loci were replicated at a nominal uncorrected p-value < 0.05. Noticeable, this study 523 had insufficient statistical power to detect variants with low MAF or small effect size, and the 524 majority of 90 risk loci had an OR of 0.8-1.2 [12]. Insufficient statistical power is likely also the reason for the lack of an identification of any loci associated with AAD. Two genome-wide 525 526 significant association signals have previously been reported to be linked to PD AAO, one at 527 the SNCA locus and one at TMEM175 [47].

528

529 Interestingly, the GWA analysis identified a novel variant, rs12771445, associated with PD at 530 a genome-wide significance level. This variant has not been reported in the PD literature and, 531 hence, may be specific for the Swedish population. Although, it could be that this common 532 variant is a tagging a population-specific rare variant as the Swedish population appear to 533 contain a substantial number of genetic variants that are not represented in other European 534 populations [26]. However, the significant variant was imputed and we remain cautious in 535 drawing any conclusions. As expected, we further identified one haplotype in PLPP4 536 significantly associated with PD. The haplotype was more common among controls, indicating 537 a decreased risk of PD among carriers. Furthermore, we investigated the joint effect of rare 538 variants (MAF<5%) in *PLPP4* on PD. Due to the low coverage of coding variants, we adapted 539 the non-burden SKAT and observed an association with PD risk for the genotyped variants but 540 not for the imputed variants. Replication studies in larger Swedish cohorts are needed in order 541 to validate our findings of a potential association between PLPP4 and PD in the Swedish 542 population.

The gene *PLPP4*, encodes for a phospholipid phosphatase that catalyzes the dephosphorylation of bioactive lipid mediators such as phosphatidic acid (PA) [68]. Another regulator of PA content, the diacylglycerol kinase, *DGKQ*, has previously been reported as a potential PD risk factor [69, 70]. The role of lipids in PD is receiving greater attention and the question whether if PD is a lipidopathy rather than a proteinopathy has been lifted [71]. Several reasons stand behind this hypothesis, including the proposal that a-synuclein is a lipid-binding protein that physiologically interacts with phospholipids and fatty acids (FAs) [71].

551

552 Although only 23 out of 90 previously reported risk variants were replicated in this Swedish 553 cohort, the cumulative GRS based on the 90 variants showed an almost five-fold higher risk 554 for PD in the highest quartile compared to the lowest quartile. Combining the GRS with 555 information on age, sex, family history of PD, and the University of Pennsylvania Smell 556 Identification Test (UPSIT) score (olfactory function) has been reported to further increase the 557 sensitivity and specificity of the PD status model [46]. Having access to all factors but the 558 UPSIT score, we added information on age, sex, family history of PD and PC1-5 to our model. 559 GRS alone gave an area under the roc curve (AUC) of 0.67 while the adjusted model gave an 560 AUC of 0.68. The non-observed difference for the two models could be due to the large 561 proportion of the variance explained by the UPSIT score in the reported prediction model 562 (63.1%) compared to the substantially lower values for GRS (13.6%), family history (11.4%), 563 gender (6.0%) and age (5.9%) [46]. The lack of association to PD in the Swedish cohort for 564 67/90 risk variants could also have an impact on the fit of the model applied in our cohort. 565 Although the model is functional enough to compare risk for disease status at a population 566 level, additional information would be needed for disease prediction. Interestingly, we 567 observed an association between the GRS and AAD despite a small sample size, with one SD

increase in the Z-standardized GRS being associated with approximately one-year earlier
AAD. This result is in concordance with previous results in other, larger, PD cohorts [22, 47].

571 Among the 90 risk variants, the LRRK2 G2019S (rs34637584) had the largest effect estimate (2.43). This variant was genotyped in our dataset but excluded during the pre-imputation QC 572 due to low MAF (0.2%). Previous studies of PD cohorts in Sweden have shown that the 573 574 prevalence of LRRK2 G2019S carriers is low in Sweden, 0.54% of screened 2206 PD patients 575 were carriers [72]. It has been estimated that the G2019S mutation worldwide accounts for 4% 576 of familial and 1% of idiopathic PD cases [73]. In our study, the fraction of carriers among the 577 patients was 0.75%, further confirming a low prevalence of LRRK2 G2019S carriers among Swedish PD patients. 578

579

In conclusion, this work represents a comprehensive description of a new PD case-control cohort from southern Sweden in which we nominate a novel GWA variant in the *PLPP4* locus. However, subsequent studies are needed in order to validate whether *PLPP4* is associated with PD within the Swedish population. This study contributes to the understanding of environmental and genetic risk factors in PD in the Swedish population, and the combination of epidemiological, clinical, and genetic data in the cohort makes it suitable for future studies of PD etiology.

587

## 588 Acknowledgments

589

590 This research was supported by MultiPark – a Strategic Research Area at Lund University and
591 by grants from the Swedish Research Council (VR), Åke Wiberg's foundation,
592 Parkinsonfonden, Åhlén foundation, Lindhés advokatbyrå, and Sigurd & Elsa Golje's

593 memorial foundation (KB/MS). This work was also supported in part by the Intramural Research Program of the National Institute on Aging (NIA) (SBC/CB), part of the National 594 595 Institutes of Health, Department of Health and Human Services. We thank the individuals who 596 have contributed and donated blood samples to MPBC. We would also like to thank the 597 research nurses and statistician Helene Jacobsson at MultiPark for conducting data collections, 598 and previous students of the Translational Neurogenetics Unit who have helped with 599 questionnaire registration to REDCap. We would like to thank Megg Garcia and Alexander 600 Svanbergsson for technical help and feedback, and the International Parkinson's Disease 601 Genomic Consortium (IPDGC) and its trainee network for additional help during the project, 602 in particularly Lynne Krohn and Manuela Tan. We would also like to acknowledge the Global 603 Parkinson's Genetics Program (GP2) learning platform for training courses and code in 604 Parkinson's disease genetics. We would also like to acknowledge Ashfaq Ali at the National 605 Bioinformatics Infrastructure Sweden at SciLifeLab for bioinformatics advice. The Region 606 Skåne Biobank Facility (BD47) has performed the biobank services in the project.

607

AP receives research support from the Swedish government (ALF), Region Skåne, Skåne University Hospital, Bundy Academy, Hans Gabriel and Alice Trolle Wachtmeister Stiftelse för Medicinsk Forskning, The Swedish Parkinson Association, The Swedish Parkinson Academy, SCA network, all in Sweden, and receives reimbursement from Elsevier Ltd. PO has received research support from The Swedish National Government and County Councils, Skåne University Hospital Foundations and Donations, Region Skåne, Parkinsonfonden, Swedish Parkinson Academy and Åhlens Foundation.

615

616

# 617 Conflict of Interest

618

619	KB, M	S, SBC, CB, AP, PO and HW have no conflicts of interest to report. OH has acquired	
620	researc	ch support (for the institution) from AVID Radiopharmaceuticals, Biogen, Eli Lilly,	
621	Eisai,	GE Healthcare, Pfizer, and Roche. In the past 2 years, he has received	
622	consul	tancy/speaker fees from AC Immune, Alzpath, Biogen, Cerveau, and Roche.	
623			
624	References		
625			
626	[1]	Collaborators GPsD (2018) Global, regional, and national burden of Parkinson's	
627		disease, 1990-2016: a systematic analysis for the Global Burden of Disease Study	
628		2016. Lancet Neurol 17, 939-953.	
629	[2]	Collaborators GBDN (2019) Global, regional, and national burden of neurological	
630		disorders, 1990-2016: a systematic analysis for the Global Burden of Disease Study	
631		2016. Lancet Neurol.	
632	[3]	Blauwendraat C, Nalls MA, Singleton AB (2020) The genetic architecture of	
633		Parkinson's disease. Lancet Neurol 19, 170-178.	
634	[4]	Bonifati V, Rizzu P, van Baren MJ, Schaap O, Breedveld GJ, Krieger E, Dekker MC,	
635		Squitieri F, Ibanez P, Joosse M, van Dongen JW, Vanacore N, van Swieten JC, Brice	
636		A, Meco G, van Duijn CM, Oostra BA, Heutink P (2003) Mutations in the DJ-1 gene	
637		associated with autosomal recessive early-onset parkinsonism. Science 299, 256-259.	
638	[5]	Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S, Yokochi	
639		M, Mizuno Y, Shimizu N (1998) Mutations in the parkin gene cause autosomal	
640		recessive juvenile parkinsonism. Nature 392, 605-608.	

- 641 [6] Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root
- 642 H, Rubenstein J, Boyer R, Stenroos ES, Chandrasekharappa S, Athanassiadou A,
- 643 Papapetropoulos T, Johnson WG, Lazzarini AM, Duvoisin RC, Di Iorio G, Golbe LI,
- 644 Nussbaum RL (1997) Mutation in the alpha-synuclein gene identified in families with
- 645 Parkinson's disease. *Science* **276**, 2045-2047.
- 646 [7] Valente EM, Abou-Sleiman PM, Caputo V, Muqit MM, Harvey K, Gispert S, Ali Z,
- 647 Del Turco D, Bentivoglio AR, Healy DG, Albanese A, Nussbaum R, González-
- 648 Maldonado R, Deller T, Salvi S, Cortelli P, Gilks WP, Latchman DS, Harvey RJ,
- 649 Dallapiccola B, Auburger G, Wood NW (2004) Hereditary early-onset Parkinson's
- disease caused by mutations in PINK1. *Science* **304**, 1158-1160.
- 651 [8] Zimprich A, Benet-Pagès A, Struhal W, Graf E, Eck SH, Offman MN, Haubenberger
- D, Spielberger S, Schulte EC, Lichtner P, Rossle SC, Klopp N, Wolf E, Seppi K,
- 653 Pirker W, Presslauer S, Mollenhauer B, Katzenschlager R, Foki T, Hotzy C,
- 654 Reinthaler E, Harutyunyan A, Kralovics R, Peters A, Zimprich F, Brücke T, Poewe
- 655 W, Auff E, Trenkwalder C, Rost B, Ransmayr G, Winkelmann J, Meitinger T, Strom
- 656 TM (2011) A mutation in VPS35, encoding a subunit of the retromer complex, causes
- 657 late-onset Parkinson disease. *Am J Hum Genet* **89**, 168-175.
- 658 [9] Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, Lincoln S, Kachergus J,
- 659 Hulihan M, Uitti RJ, Calne DB, Stoessl AJ, Pfeiffer RF, Patenge N, Carbajal IC,
- 660 Vieregge P, Asmus F, Müller-Myhsok B, Dickson DW, Meitinger T, Strom TM,
- 661 Wszolek ZK, Gasser T (2004) Mutations in LRRK2 cause autosomal-dominant
- 662 parkinsonism with pleomorphic pathology. *Neuron* **44**, 601-607.
- 663 [10] de Lau LM, Breteler MM (2006) Epidemiology of Parkinson's disease. *Lancet Neurol*664 5, 525-535.

665	[11]	Vollstedt EJ, Kasten M, Klein C (2019) Using global team science to identify genetic
666		parkinson's disease worldwide. Ann Neurol 86, 153-157.
667	[12]	Nalls MA, Blauwendraat C, Vallerga CL, Heilbron K, Bandres-Ciga S, Chang D, Tan
668		M, Kia DA, Noyce AJ, Xue A, Bras J, Young E, von Coelln R, Simón-Sánchez J,
669		Schulte C, Sharma M, Krohn L, Pihlstrøm L, Siitonen A, Iwaki H, Leonard H, Faghri
670		F, Gibbs JR, Hernandez DG, Scholz SW, Botia JA, Martinez M, Corvol J-C, Lesage
671		S, Jankovic J, Shulman LM, Sutherland M, Tienari P, Majamaa K, Toft M,
672		Andreassen OA, Bangale T, Brice A, Yang J, Gan-Or Z, Gasser T, Heutink P,
673		Shulman JM, Wood NW, Hinds DA, Hardy JA, Morris HR, Gratten J, Visscher PM,
674		Graham RR, Singleton AB, and Me Research T, System Genomics of Parkinson's
675		Disease C, International Parkinson's Disease Genomics C (2019) Identification of
676		novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-
677		analysis of genome-wide association studies. The Lancet. Neurology 18, 1091-1102.
678	[13]	Foo JN, Chew EGY, Chung SJ, Peng R, Blauwendraat C, Nalls MA, Mok KY, Satake
679		W, Toda T, Chao Y, Tan LCS, Tandiono M, Lian MM, Ng EY, Prakash KM, Au WL,
680		Meah WY, Mok SQ, Annuar AA, Chan AYY, Chen L, Chen Y, Jeon BS, Jiang L,
681		Lim JL, Lin JJ, Liu C, Mao C, Mok V, Pei Z, Shang HF, Shi CH, Song K, Tan AH,

682 Wu YR, Xu YM, Xu R, Yan Y, Yang J, Zhang B, Koh WP, Lim SY, Khor CC, Liu J,

683Tan EK (2020) Identification of Risk Loci for Parkinson Disease in Asians and

- 684 Comparison of Risk Between Asians and Europeans: A Genome-Wide Association
- 685 Study. *JAMA Neurol* **77**, 746-754.
- 686 [14] Génin E (2020) Missing heritability of complex diseases: case solved? *Human*687 *Genetics* 139, 103-113.
- 688 [15] Young AI (2019) Solving the missing heritability problem. *PLoS Genet* 15,
  689 e1008222.

- 690 [16] Noyce AJ, Bestwick JP, Silveira-Moriyama L, Hawkes CH, Giovannoni G, Lees AJ,
- 691 Schrag A (2012) Meta-analysis of early nonmotor features and risk factors for
- 692 Parkinson disease. Ann Neurol 72, 893-901.
- 693 [17] Bellou V, Belbasis L, Tzoulaki I, Evangelou E, Ioannidis JP (2016) Environmental
- 694 risk factors and Parkinson's disease: An umbrella review of meta-analyses.
- 695 *Parkinsonism Relat Disord* 23, 1-9.
- 696 [18] Sirugo G, Williams SM, Tishkoff SA (2019) The Missing Diversity in Human
  697 Genetic Studies. *Cell* 177, 26-31.
- 698 [19] Popejoy AB, Fullerton SM (2016) Genomics is failing on diversity. *Nature* 538, 161699 164.
- 700 [20] International Parkinson Disease Genomics C (2020) Ten Years of the International
- Parkinson Disease Genomics Consortium: Progress and Next Steps. *Journal of Parkinson's disease* 10, 19-30.
- 703 [21] Loesch DP, Horimoto A, Heilbron K, Sarihan EI, Inca-Martinez M, Mason E,
- 704 Cornejo-Olivas M, Torres L, Mazzetti P, Cosentino C, Sarapura-Castro E, Rivera-
- 705 Valdivia A, Medina AC, Dieguez E, Raggio V, Lescano A, Tumas V, Borges V,
- 706 Ferraz HB, Rieder CR, Schumacher-Schuh A, Santos-Lobato BL, Velez-Pardo C,
- 707 Jimenez-Del-Rio M, Lopera F, Moreno S, Chana-Cuevas P, Fernandez W, Arboleda
- 708 G, Arboleda H, Arboleda-Bustos CE, Yearout D, Zabetian CP, Cannon P, Thornton
- 709 TA, O'Connor TD, Mata IF (2021) Characterizing the Genetic Architecture of
- 710 Parkinson's Disease in Latinos. *Ann Neurol*.
- 711 [22] Bandres-Ciga S, Ahmed S, Sabir MS, Blauwendraat C, Adarmes-Gómez AD, Bernal-
- 712 Bernal I, Bonilla-Toribio M, Buiza-Rueda D, Carrillo F, Carrión-Claro M, Gómez-
- 713 Garre P, Jesús S, Labrador-Espinosa MA, Macias D, Méndez-Del-Barrio C, Periñán-
- 714 Tocino T, Tejera-Parrado C, Vargas-González L, Diez-Fairen M, Alvarez I, Tartari

715		JP, Buongiorno M, Aguilar M, Gorostidi A, Bergareche JA, Mondragon E, Vinagre-
716		Aragon A, Croitoru I, Ruiz-Martínez J, Dols-Icardo O, Kulisevsky J, Marín-Lahoz J,
717		Pagonabarraga J, Pascual-Sedano B, Ezquerra M, Cámara A, Compta Y, Fernández
718		M, Fernández-Santiago R, Muñoz E, Tolosa E, Valldeoriola F, Gonzalez-Aramburu I,
719		Sanchez Rodriguez A, Sierra M, Menéndez-González M, Blazquez M, Garcia C,
720		Suarez-San Martin E, García-Ruiz P, Martínez-Castrillo JC, Vela-Desojo L, Ruz C,
721		Barrero FJ, Escamilla-Sevilla F, Mínguez-Castellanos A, Cerdan D, Tabernero C,
722		Gomez Heredia MJ, Perez Errazquin F, Romero-Acebal M, Feliz C, Lopez-Sendon
723		JL, Mata M, Martínez Torres I, Kim JJ, Dalgard CL, American Genome C, Brooks J,
724		Saez-Atienzar S, Gibbs JR, Jorda R, Botia JA, Bonet-Ponce L, Morrison KE, Clarke
725		C, Tan M, Morris H, Edsall C, Hernandez D, Simon-Sanchez J, Nalls MA, Scholz
726		SW, Jimenez-Escrig A, Duarte J, Vives F, Duran R, Hoenicka J, Alvarez V, Infante J,
727		Marti MJ, Clarimón J, López de Munain A, Pastor P, Mir P, Singleton A,
728		International Parkinson Disease Genomics C (2019) The Genetic Architecture of
729		Parkinson Disease in Spain: Characterizing Population-Specific Risk, Differential
730		Haplotype Structures, and Providing Etiologic Insight. Movement disorders : official
731		journal of the Movement Disorder Society 34, 1851-1863.
732	[23]	Pihlstrøm L, Axelsson G, Bjørnarå KA, Dizdar N, Fardell C, Forsgren L, Holmberg
733		B, Larsen JP, Linder J, Nissbrandt H, Tysnes OB, Ohman E, Dietrichs E, Toft M
734		(2013) Supportive evidence for 11 loci from genome-wide association studies in
735		Parkinson's disease. Neurobiol Aging 34, 1708.e1707-1713.
736	[24]	Humphreys K, Grankvist A, Leu M, Hall P, Liu J, Ripatti S, Rehnström K, Groop L,
737		Klareskog L, Ding B, Grönberg H, Xu J, Pedersen NL, Lichtenstein P, Mattingsdal
738		M, Andreassen OA, O'Dushlaine C, Purcell SM, Sklar P, Sullivan PF, Hultman CM,

739	Palmgren J, Magnusson PKE (2011) The genetic structure of the Swedish population.
740	<i>PloS one</i> <b>6</b> , e22547-e22547.

- 741 [25] Nelis M, Esko T, Mägi R, Zimprich F, Zimprich A, Toncheva D, Karachanak S,
- 742 Piskácková T, Balascák I, Peltonen L, Jakkula E, Rehnström K, Lathrop M, Heath S,
- Galan P, Schreiber S, Meitinger T, Pfeufer A, Wichmann HE, Melegh B, Polgár N,
- 744 Toniolo D, Gasparini P, D'Adamo P, Klovins J, Nikitina-Zake L, Kucinskas V,
- 745 Kasnauskiene J, Lubinski J, Debniak T, Limborska S, Khrunin A, Estivill X, Rabionet
- 746 R, Marsal S, Julià A, Antonarakis SE, Deutsch S, Borel C, Attar H, Gagnebin M,
- 747 Macek M, Krawczak M, Remm M, Metspalu A (2009) Genetic structure of
- Europeans: a view from the North-East. *PloS one* **4**, e5472-e5472.
- 749 [26] Ameur A, Dahlberg J, Olason P, Vezzi F, Karlsson R, Martin M, Viklund J, Kähäri
- AK, Lundin P, Che H, Thutkawkorapin J, Eisfeldt J, Lampa S, Dahlberg M, Hagberg
- 751 J, Jareborg N, Liljedahl U, Jonasson I, Johansson Å, Feuk L, Lundeberg J, Syvänen
- AC, Lundin S, Nilsson D, Nystedt B, Magnusson PK, Gyllensten U (2017) SweGen:
- a whole-genome data resource of genetic variability in a cross-section of the Swedish
- 754 population. *Eur J Hum Genet* **25**, 1253-1260.
- 755 [27] Salmela E, Lappalainen T, Liu J, Sistonen P, Andersen PM, Schreiber S, Savontaus
- 756 M-L, Czene K, Lahermo P, Hall P, Kere J (2011) Swedish population substructure

revealed by genome-wide single nucleotide polymorphism data. *PloS one* 6, e16747e16747.

- 759 [28] Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG (2009) Research
- 760 electronic data capture (REDCap)—A metadata-driven methodology and workflow
- 761 process for providing translational research informatics support. *Journal of*
- 762 Biomedical Informatics 42, 377-381.
- 763 [29] R Core Team (2020) R Foundation for Statistical Computing, Vienna, Austria.

- 764 [30] Burström K, Sun S, Gerdtham UG, Henriksson M, Johannesson M, Levin L,
- 765 Zethraeus N (2014) Swedish experience-based value sets for EQ-5D health states.
- 766 *Qual Life Res* **23**, 431-442.
- 767 [31] Burström K, Teni FS, Gerdtham UG, Leidl R, Helgesson G, Rolfson O, Henriksson
- M (2020) Experience-Based Swedish TTO and VAS Value Sets for EQ-5D-5L Health
  States. *Pharmacoeconomics* 38, 839-856.
- 770 [32] Textor J, van der Zander B, Gilthorpe MS, Liśkiewicz M, Ellison GTH (2016) Robust
  771 causal inference using directed acyclic graphs: the R package 'dagitty'. *International*772 *Journal of Epidemiology* 45, 1887-1894.
- 773 [33] Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J,
- 774 Sklar P, de Bakker PI, Daly MJ, Sham PC (2007) PLINK: a tool set for whole-
- genome association and population-based linkage analyses. *Am J Hum Genet* 81, 559575.
- 777 [34] Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ (2015) Second-
- 778 generation PLINK: rising to the challenge of larger and richer datasets. *Gigascience*
- **4**, 7.
- 780 [35] Gibbs RA, Belmont JW, Hardenbol P, Willis TD, Yu F, Yang H, Ch'ang L-Y, Huang
- 781 W, Liu B, Shen Y, Tam PK-H, Tsui L-C, Waye MMY, Wong JT-F, Zeng C, Zhang
- 782 Q, Chee MS, Galver LM, Kruglyak S, Murray SS, Oliphant AR, Montpetit A, Hudson
- 783 TJ, Chagnon F, Ferretti V, Leboeuf M, Phillips MS, Verner A, Kwok P-Y, Duan S,
- 784 Lind DL, Miller RD, Rice JP, Saccone NL, Taillon-Miller P, Xiao M, Nakamura Y,
- 785 Sekine A, Sorimachi K, Tanaka T, Tanaka Y, Tsunoda T, Yoshino E, Bentley DR,
- 786 Deloukas P, Hunt S, Powell D, Altshuler D, Gabriel SB, Zhang H, Zeng C, Matsuda I,
- 787 Fukushima Y, Macer DR, Suda E, Rotimi CN, Adebamowo CA, Aniagwu T,
- 788 Marshall PA, Matthew O, Nkwodimmah C, Royal CDM, Leppert MF, Dixon M,

789	Stein LD, Cunningham F, Kanani A, Thorisson GA, Chakravarti A, Chen PE, Cutler
790	DJ, Kashuk CS, Donnelly P, Marchini J, McVean GAT, Myers SR, Cardon LR,
791	Abecasis GR, Morris A, Weir BS, Mullikin JC, Sherry ST, Feolo M, Altshuler D,
792	Daly MJ, Schaffner SF, Qiu R, Kent A, Dunston GM, Kato K, Niikawa N, Knoppers
793	BM, Foster MW, Clayton EW, Wang VO, Watkin J, Gibbs RA, Belmont JW,
794	Sodergren E, Weinstock GM, Wilson RK, Fulton LL, Rogers J, Birren BW, Han H,
795	Wang H, Godbout M, Wallenburg JC, L'Archevêque P, Bellemare G, Todani K,
796	Fujita T, Tanaka S, Holden AL, Lai EH, Collins FS, Brooks LD, McEwen JE, Guyer
797	MS, Jordan E, Peterson JL, Spiegel J, Sung LM, Zacharia LF, Kennedy K, Dunn MG,
798	Seabrook R, Shillito M, Skene B, Stewart JG, Valle DL, Clayton EW, Jorde LB,
799	Belmont JW, Chakravarti A, Cho MK, Duster T, Foster MW, Jasperse M, Knoppers
800	BM, Kwok P-Y, Licinio J, Long JC, Marshall PA, Ossorio PN, Wang VO, Rotimi
801	CN, Royal CDM, Spallone P, Terry SF, Lander ES, Lai EH, Nickerson DA, Abecasis
802	GR, Altshuler D, Bentley DR, Boehnke M, Cardon LR, Daly MJ, Deloukas P,
803	Douglas JA, Gabriel SB, Hudson RR, Hudson TJ, Kruglyak L, Kwok P-Y, Nakamura
804	Y, Nussbaum RL, Royal CDM, Schaffner SF, Sherry ST, Stein LD, Tanaka T, †The
805	International HapMap C, Genotyping centres: Baylor College of M, ParAllele B,
806	Chinese HapMap C, Illumina, McGill U, Génome Québec Innovation C, University
807	of California at San F, Washington U, University of T, Riken, Wellcome Trust Sanger
808	I, Whitehead Institute MITCfGR, Community engagement/public c, sample-
809	collection groups: Beijing Normal U, Beijing Genomics I, Health Sciences University
810	of Hokkaido EEI, Shinshu U, Howard U, University of I, University of U, Analysis
811	Groups: Cold Spring Harbor L, Johns Hopkins University School of M, University of
812	O, University of Oxford WTCfHG, Health USNIo, Ethical L, Social Issues: Chinese
813	Academy of Social S, Genetic Interest G, Howard U, Kyoto U, Nagasaki U,

814		University of M, University of O, Vanderbilt U, Wellcome T, Medicine SNPDBCo,
815		Washington U, Scientific Management: Chinese Academy of S, Chinese Ministry of
816		S, Technology, Genome C, Génome Q, Japanese Ministry of Education CSS,
817		Technology, The SNPC, Initial Planning Groups P, Ethical L, Social Issues G,
818		Methods G (2003) The International HapMap Project. Nature 426, 789-796.
819	[36]	Das S, Forer L, Schonherr S, Sidore C, Locke AE, Kwong A, Vrieze SI, Chew EY,
820		Levy S, McGue M, Schlessinger D, Stambolian D, Loh PR, Iacono WG, Swaroop A,
821		Scott LJ, Cucca F, Kronenberg F, Boehnke M, Abecasis GR, Fuchsberger C (2016)
822		Next-generation genotype imputation service and methods. Nat Genet 48, 1284-1287.
823	[37]	Loh PR, Danecek P, Palamara PF, Fuchsberger C, Y AR, H KF, Schoenherr S, Forer
824		L, McCarthy S, Abecasis GR, Durbin R, A LP (2016) Reference-based phasing using
825		the Haplotype Reference Consortium panel. Nat Genet 48, 1443-1448.
826	[38]	McCarthy S, Das S, Kretzschmar W, Delaneau O, Wood AR, Teumer A, Kang HM,
827		Fuchsberger C, Danecek P, Sharp K, Luo Y, Sidore C, Kwong A, Timpson N,
828		Koskinen S, Vrieze S, Scott LJ, Zhang H, Mahajan A, Veldink J, Peters U, Pato C,
829		van Duijn CM, Gillies CE, Gandin I, Mezzavilla M, Gilly A, Cocca M, Traglia M,
830		Angius A, Barrett JC, Boomsma D, Branham K, Breen G, Brummett CM, Busonero
831		F, Campbell H, Chan A, Chen S, Chew E, Collins FS, Corbin LJ, Smith GD,
832		Dedoussis G, Dorr M, Farmaki AE, Ferrucci L, Forer L, Fraser RM, Gabriel S, Levy
833		S, Groop L, Harrison T, Hattersley A, Holmen OL, Hveem K, Kretzler M, Lee JC,
834		McGue M, Meitinger T, Melzer D, Min JL, Mohlke KL, Vincent JB, Nauck M,
835		Nickerson D, Palotie A, Pato M, Pirastu N, McInnis M, Richards JB, Sala C, Salomaa
836		V, Schlessinger D, Schoenherr S, Slagboom PE, Small K, Spector T, Stambolian D,
837		Tuke M, Tuomilehto J, Van den Berg LH, Van Rheenen W, Volker U, Wijmenga C,
838		Toniolo D, Zeggini E, Gasparini P, Sampson MG, Wilson JF, Frayling T, de Bakker

- 839 PI, Swertz MA, McCarroll S, Kooperberg C, Dekker A, Altshuler D, Willer C, Iacono
- 840 W, Ripatti S, Soranzo N, Walter K, Swaroop A, Cucca F, Anderson CA, Myers RM,
- 841 Boehnke M, McCarthy MI, Durbin R (2016) A reference panel of 64,976 haplotypes
- for genotype imputation. *Nat Genet* **48**, 1279-1283.
- 843 [39] Zhan X, Hu Y, Li B, Abecasis GR, Liu DJ (2016) RVTESTS: an efficient and
- 844 comprehensive tool for rare variant association analysis using sequence data.
- 845 *Bioinformatics* **32**, 1423-1426.
- 846 [40] Wang K, Li M, Hakonarson H (2010) ANNOVAR: functional annotation of genetic
- 847 variants from high-throughput sequencing data. *Nucleic Acids Res* **38**, e164.
- 848 [41] Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, Blumenstiel B, Higgins J,
- 849 DeFelice M, Lochner A, Faggart M, Liu-Cordero SN, Rotimi C, Adeyemo A, Cooper
- 850 R, Ward R, Lander ES, Daly MJ, Altshuler D (2002) The structure of haplotype
- blocks in the human genome. *Science* **296**, 2225-2229.
- 852 [42] Barrett JC, Fry B, Maller J, Daly MJ (2005) Haploview: analysis and visualization of
  853 LD and haplotype maps. *Bioinformatics* 21, 263-265.
- [43] Uhl GR, Drgon T, Johnson C, Walther D, David SP, Aveyard P, Murphy M,
- 355 Johnstone EC, Munafò MR (2010) Genome-wide association for smoking cessation
- success: participants in the Patch in Practice trial of nicotine replacement.
- 857 *Pharmacogenomics* **11**, 357-367.
- 858 [44] Barrett JC, Fry B, Maller J, Daly MJ (2005) Haploview: analysis and visualization of
  859 LD and haplotype maps. *Bioinformatics* 21, 263-265.
- 860 [45] Lee S, Emond MJ, Bamshad MJ, Barnes KC, Rieder MJ, Nickerson DA, Christiani
- 861 DC, Wurfel MM, Lin X (2012) Optimal unified approach for rare-variant association
- testing with application to small-sample case-control whole-exome sequencing
- 863 studies. *Am J Hum Genet* **91**, 224-237.

864	[46]	Nalls MA, McLean CY, Rick J, Eberly S, Hutten SJ, Gwinn K, Sutherland M,
865	[]	Martinez M, Heutink P, Williams NM, Hardy J, Gasser T, Brice A, Price TR, Nicolas
866		A, Keller MF, Molony C, Gibbs JR, Chen-Plotkin A, Suh E, Letson C, Fiandaca MS,
867		Mapstone M, Federoff HJ, Noyce AJ, Morris H, Van Deerlin VM, Weintraub D,
868		Zabetian C, Hernandez DG, Lesage S, Mullins M, Conley ED, Northover CAM,
869		Frasier M, Marek K, Day-Williams AG, Stone DJ, Ioannidis JPA, Singleton AB,
870		Parkinson's Disease Biomarkers P, Parkinson's Progression Marker Initiative i (2015)
871		Diagnosis of Parkinson's disease on the basis of clinical and genetic classification: a
872		population-based modelling study. The Lancet. Neurology 14, 1002-1009.
873	[47]	Blauwendraat C, Heilbron K, Vallerga CL, Bandres-Ciga S, von Coelln R, Pihlstrom
874		L, Simon-Sanchez J, Schulte C, Sharma M, Krohn L, Siitonen A, Iwaki H, Leonard
875		H, Noyce AJ, Tan M, Gibbs JR, Hernandez DG, Scholz SW, Jankovic J, Shulman
876		LM, Lesage S, Corvol JC, Brice A, van Hilten JJ, Marinus J, Eerola-Rautio J, Tienari
877		P, Majamaa K, Toft M, Grosset DG, Gasser T, Heutink P, Shulman JM, Wood N,
878		Hardy J, Morris HR, Hinds DA, Gratten J, Visscher PM, Gan-Or Z, Nalls MA,
879		Singleton AB (2019) Parkinson's disease age at onset genome-wide association study:
880		Defining heritability, genetic loci, and alpha-synuclein mechanisms. Mov Disord.
881	[48]	Taliun D, Harris DN, Kessler MD, Carlson J, Szpiech ZA, Torres R, Taliun SAG,
882		Corvelo A, Gogarten SM, Kang HM, Pitsillides AN, LeFaive J, Lee S-b, Tian X,
883		Browning BL, Das S, Emde A-K, Clarke WE, Loesch DP, Shetty AC, Blackwell TW,
884		Smith AV, Wong Q, Liu X, Conomos MP, Bobo DM, Aguet F, Albert C, Alonso A,
885		Ardlie KG, Arking DE, Aslibekyan S, Auer PL, Barnard J, Barr RG, Barwick L,
886		Becker LC, Beer RL, Benjamin EJ, Bielak LF, Blangero J, Boehnke M, Bowden DW,
887		Brody JA, Burchard EG, Cade BE, Casella JF, Chalazan B, Chasman DI, Chen Y-DI,
888		Cho MH, Choi SH, Chung MK, Clish CB, Correa A, Curran JE, Custer B, Darbar D,

889	Daya M, de Andrade M, DeMeo DL, Dutcher SK, Ellinor PT, Emery LS, Eng C,
890	Fatkin D, Fingerlin T, Forer L, Fornage M, Franceschini N, Fuchsberger C, Fullerton
891	SM, Germer S, Gladwin MT, Gottlieb DJ, Guo X, Hall ME, He J, Heard-Costa NL,
892	Heckbert SR, Irvin MR, Johnsen JM, Johnson AD, Kaplan R, Kardia SLR, Kelly T,
893	Kelly S, Kenny EE, Kiel DP, Klemmer R, Konkle BA, Kooperberg C, Köttgen A,
894	Lange LA, Lasky-Su J, Levy D, Lin X, Lin K-H, Liu C, Loos RJF, Garman L,
895	Gerszten R, Lubitz SA, Lunetta KL, Mak ACY, Manichaikul A, Manning AK,
896	Mathias RA, McManus DD, McGarvey ST, Meigs JB, Meyers DA, Mikulla JL,
897	Minear MA, Mitchell BD, Mohanty S, Montasser ME, Montgomery C, Morrison AC,
898	Murabito JM, Natale A, Natarajan P, Nelson SC, North KE, O'Connell JR, Palmer
899	ND, Pankratz N, Peloso GM, Peyser PA, Pleiness J, Post WS, Psaty BM, Rao DC,
900	Redline S, Reiner AP, Roden D, Rotter JI, Ruczinski I, Sarnowski C, Schoenherr S,
901	Schwartz DA, Seo J-S, Seshadri S, Sheehan VA, Sheu WH, Shoemaker MB, Smith
902	NL, Smith JA, Sotoodehnia N, Stilp AM, Tang W, Taylor KD, Telen M, Thornton
903	TA, Tracy RP, Van Den Berg DJ, Vasan RS, Viaud-Martinez KA, Vrieze S, Weeks
904	DE, Weir BS, Weiss ST, Weng L-C, Willer CJ, Zhang Y, Zhao X, Arnett DK,
905	Ashley-Koch AE, Barnes KC, Boerwinkle E, Gabriel S, Gibbs R, Rice KM, Rich SS,
906	Silverman EK, Qasba P, Gan W, Abe N, Almasy L, Ament S, Anderson P, Anugu P,
907	Applebaum-Bowden D, Assimes T, Avramopoulos D, Barron-Casella E, Beaty T,
908	Beck G, Becker D, Beitelshees A, Benos T, Bezerra M, Bis J, Bowler R, Broeckel U,
909	Broome J, Bunting K, Bustamante C, Buth E, Cardwell J, Carey V, Carty C, Casaburi
910	R, Castaldi P, Chaffin M, Chang C, Chang Y-C, Chavan S, Chen B-J, Chen W-M,
911	Chuang L-M, Chung R-H, Comhair S, Cornell E, Crandall C, Crapo J, Curtis J,
912	Damcott C, David S, Davis C, Fuentes Ldl, DeBaun M, Deka R, Devine S, Duan Q,
913	Duggirala R, Durda JP, Eaton C, Ekunwe L, El Boueiz A, Erzurum S, Farber C,

37

914 Flickinger M, Fornage M, Frazar C, Fu M, Fulton L, Gao S, Gao Y, Gass M, Gelt	914	Flickinger M	. Fornage M.	Frazar C.	. Fu M.	Fulton L.	Gao S.	Gao Y.	Gass M.	Gelb
---	-----	--------------	--------------	-----------	---------	-----------	--------	--------	---------	------

- 915 Geng XP, Geraci M, Ghosh A, Gignoux C, Glahn D, Gong D-W, Goring H, Graw S,
- 916 Grine D, Gu CC, Guan Y, Gupta N, Haessler J, Hawley NL, Heavner B, Herrington
- 917 D, Hersh C, Hidalgo B, Hixson J, Hobbs B, Hokanson J, Hong E, Hoth K, Hsiung
- 918 CA, Hung Y-J, Huston H, Hwu CM, Jackson R, Jain D, Jhun MA, Johnson C,
- 919 Johnston R, Jones K, Kathiresan S, Khan A, Kim W, Kinney G, Kramer H, Lange C,
- 920 Lange E, Lange L, Laurie C, LeBoff M, Lee J, Lee SS, Lee W-J, Levine D, Lewis J,
- 921 Li X, Li Y, Lin H, Lin H, Lin KH, Liu S, Liu Y, Liu Y, Luo J, Mahaney M,
- 922 Consortium NT-OfPM (2021) Sequencing of 53,831 diverse genomes from the
- 923 NHLBI TOPMed Program. Nature 590, 290-299.
- 924 [49] Schapira AHV, Chaudhuri KR, Jenner P (2017) Non-motor features of Parkinson 925 disease. Nature Reviews Neuroscience 18, 435-450.
- 926 [50] Kashihara K (2006) Weight loss in Parkinson's disease. J Neurol 253 Suppl 7, Vii38-41.
- 927
- [51] Pandey S, Srivanitchapoom P (2017) Levodopa-induced Dyskinesia: Clinical 928
- 929 Features, Pathophysiology, and Medical Management. Annals of Indian Academy of 930 Neurology 20, 190-198.
- 931 Freire C, Koifman S (2012) Pesticide exposure and Parkinson's disease: [52]
- 932 Epidemiological evidence of association. NeuroToxicology 33, 947-971.
- 933 KEMI, Statistics on pesticides, Swedish Chemicals Agency, [53]
- 934 https://www.kemi.se/en/statistics-on-chemicals-in-sweden/statistics-on-pesticides,
- 935 November 27 2020, Accessed May 5 2021.
- 936 [54] Sellbach AN, Boyle RS, Silburn PA, Mellick GD (2006) Parkinson's disease and
- 937 family history. Parkinsonism & Related Disorders 12, 399-409.

938	[55]	Marras C, Hincapié CA, Kristman VL, Cancelliere C, Soklaridis S, Li A, Borg J, af
939		Geijerstam JL, Cassidy JD (2014) Systematic review of the risk of Parkinson's disease
940		after mild traumatic brain injury: results of the International Collaboration on Mild
941		Traumatic Brain Injury Prognosis. Arch Phys Med Rehabil 95, S238-244.
942	[56]	Jafari S, Etminan M, Aminzadeh F, Samii A (2013) Head injury and risk of Parkinson
943		disease: a systematic review and meta-analysis. Mov Disord 28, 1222-1229.
944	[57]	Holm H, Jarvis MJ, Russell MA, Feyerabend C (1992) Nicotine intake and
945		dependence in Swedish snuff takers. Psychopharmacology (Berl) 108, 507-511.
946	[58]	Yang F, Pedersen NL, Ye W, Liu Z, Norberg M, Forsgren L, Trolle Lagerros Y,
947		Bellocco R, Alfredsson L, Knutsson A, Jansson JH, Wennberg P, Galanti MR, Lager
948		ACJ, Araghi M, Lundberg M, Magnusson C, Wirdefeldt K (2017) Moist smokeless
949		tobacco (Snus) use and risk of Parkinson's disease. Int J Epidemiol 46, 872-880.
950	[59]	Tobacco, Public Health Agency of Sweden,
951		https://www.folkhalsomyndigheten.se/the-public-health-agency-of-sweden/living-
952		conditions-and-lifestyle/alcohol-narcotics-doping-tobacco-and-gambling/tobacco/,
953		June 28 2019, Accessed April 20.
954	[60]	Quik M (2004) Smoking, nicotine and Parkinson's disease. Trends in Neurosciences
955		<b>27</b> , 561-568.
956	[61]	Hou L, Li Q, Jiang L, Qiu H, Geng C, Hong J-S, Li H, Wang Q (2018) Hypertension
957		and Diagnosis of Parkinson's Disease: A Meta-Analysis of Cohort Studies. Frontiers
958		in neurology <b>9</b> , 162-162.
959	[62]	Jiang Z, Xu X, Gu X, Ou R, Luo X, Shang H, Song W (2020) Effects of Higher
960		Serum Lipid Levels on the Risk of Parkinson's Disease: A Systematic Review and
961		Meta-Analysis. Front Neurol 11, 597.

962	[63]	Yan J, Qiao L, Tian J, Liu A, Wu J, Huang J, Shen M, Lai X (2019) Effect of statins
963		on Parkinson's disease: A systematic review and meta-analysis. Medicine 98.
964	[64]	Jones JD, Malaty I, Price CC, Okun MS, Bowers D (2012) Health comorbidities and
965		cognition in 1948 patients with idiopathic Parkinson's disease. Parkinsonism Relat
966		Disord 18, 1073-1078.
967	[65]	Rugbjerg K, Friis S, Jørgensen TL, Ritz B, Korbo L, Olsen JH (2010) Risk for
968		Parkinson's disease among patients with osteoarthritis: a Danish cohort study. Mov
969		Disord 25, 2355-2360.
970	[66]	Gao X, Chen H, Schwarzschild MA, Ascherio A (2011) Use of ibuprofen and risk of
971		Parkinson disease. Neurology 76, 863-869.
972	[67]	Brakedal B, Tzoulis C, Tysnes OB, Haugarvoll K (2021) NSAID use is not associated
973		with Parkinson's disease incidence: A Norwegian Prescription Database study. PLoS
974		<i>One</i> <b>16</b> , e0256602.
975	[68]	Zhang X, Zhang L, Lin B, Chai X, Li R, Liao Y, Deng X, Liu Q, Yang W, Cai Y,
976		Zhou W, Lin Z, Huang W, Zhong M, Lei F, Wu J, Yu S, Li X, Li S, Li Y, Zeng J,
977		Long W, Ren D, Huang Y (2017) Phospholipid Phosphatase 4 promotes proliferation
978		and tumorigenesis, and activates Ca(2+)-permeable Cationic Channel in lung
979		carcinoma cells. Mol Cancer 16, 147.
980	[69]	Simón-Sánchez J, van Hilten JJ, van de Warrenburg B, Post B, Berendse HW,
981		Arepalli S, Hernandez DG, de Bie RM, Velseboer D, Scheffer H, Bloem B, van Dijk
982		KD, Rivadeneira F, Hofman A, Uitterlinden AG, Rizzu P, Bochdanovits Z, Singleton
983		AB, Heutink P (2011) Genome-wide association study confirms extant PD risk loci
984		among the Dutch. Eur J Hum Genet 19, 655-661.
985	[70]	Nalls MA, Pankratz N, Lill CM, Do CB, Hernandez DG, Saad M, DeStefano AL,
986		Kara E, Bras J, Sharma M, Schulte C, Keller MF, Arepalli S, Letson C, Edsall C,

40

987		Stefansson H, Liu X, Pliner H, Lee JH, Cheng R, International Parkinson's Disease
988		Genomics C, Parkinson's Study Group Parkinson's Research: The Organized GI,
989		andMe, GenePd, NeuroGenetics Research C, Hussman Institute of Human G,
990		Ashkenazi Jewish Dataset I, Cohorts for H, Aging Research in Genetic E, North
991		American Brain Expression C, United Kingdom Brain Expression C, Greek
992		Parkinson's Disease C, Alzheimer Genetic Analysis G, Ikram MA, Ioannidis JPA,
993		Hadjigeorgiou GM, Bis JC, Martinez M, Perlmutter JS, Goate A, Marder K, Fiske B,
994		Sutherland M, Xiromerisiou G, Myers RH, Clark LN, Stefansson K, Hardy JA,
995		Heutink P, Chen H, Wood NW, Houlden H, Payami H, Brice A, Scott WK, Gasser T,
996		Bertram L, Eriksson N, Foroud T, Singleton AB (2014) Large-scale meta-analysis of
997		genome-wide association data identifies six new risk loci for Parkinson's disease.
998		<i>Nature genetics</i> <b>46</b> , 989-993.
999	[71]	Fanning S, Selkoe D, Dettmer U (2020) Parkinson's disease: proteinopathy or
1000		lipidopathy? npj Parkinson's Disease 6, 3.
1001	[72]	Puschmann A, Jiménez-Ferrer I, Lundblad-Andersson E, Mårtensson E, Hansson O,
1002		Odin P, Widner H, Brolin K, Mzezewa R, Kristensen J, Soller M, Rödström EY, Ross
1003		OA, Toft M, Breedveld GJ, Bonifati V, Brodin L, Zettergren A, Sydow O, Linder J,
1004		Wirdefeldt K, Svenningsson P, Nissbrandt H, Belin AC, Forsgren L, Swanberg M
1005		(2019) Low prevalence of known pathogenic mutations in dominant PD genes: A
1006		Swedish multicenter study. Parkinsonism & related disorders 66, 158-165.
1007	[73]	Tolosa E, Vila M, Klein C, Rascol O (2020) LRRK2 in Parkinson disease: challenges
1008		of clinical trials. Nature Reviews Neurology 16, 97-107.
1009		
1010		

1010

## Tables

### Table 1: Characteristics of participants (individuals with Parkinson's disease (PD) and

	Patients (N=929)	Controls (N=935)
Sex		
n	929	935
Men	599 (64.5%)	598 (64.0%)
Women	330 (35.5%)	337 (36.0%)
Birth year		
n	929	935
Mean (SD)	1944.4 (8.4)	1944.4 (8.3)
Range	1920.0-1979.0	1920.0-1980.0
Age at inclusion		
n	929	935
Mean (SD)	71.0 (8.3)	72.3 (8.3)
Range	37.0-96.0	38.0-97.0
Swedish ancestry		
n	922	921
No	112 (12.1%)	128 (13.9%)
Yes	810 (87.9%)	793 (86.1%)
Highest completed education		
n	923	929
< Primary and lower secondary education	8 (0.9%)	4 (0.4%)
Primary and lower secondary education	241 (26.1%)	232 (25.0%)
Upper secondary education	403 (43.7%)	384 (41.3%)
University	271 (29.4%)	309 (33.3%)
BMI at inclusion (kg/m <sup>2</sup> )		
n	914	921
Mean (SD)	25.8 (4.4)	26.0 (3.9)
Range	15.2-48.8	15.9-42.3
Marital status		
n	925	931
Single	57 (6.2%)	62 (6.7%)
Married/Civil partnership	719 (77.7%)	713 (76.6%)
Divorced/Separated	71 (7.7%)	60 (6.4%)
Widow/Widower	78 (8.4%)	96 (10.3%)
TTO Index		
n	898	903
Mean (SD)	0.8 (0.1)	0.9 (0.1)
Range	0.4-1.0	0.5-1.0
VAS Index		
n	898	903
Mean (SD)	68.9 (16.8)	82.0 (9.7)
Range	17.2-88.9	20.9-88.9

Swedish ancestry: Both parents were born in Sweden. BMI: Body Mass Index; TTO: Time Trade Of, EQ-5D-3L;

VAS: Visual Analogue Scale, EQ-5D-3L

### Table 2: Characteristics of individuals with Parkinson's disease in the MPBC cohort.

	Men (N=599)	Women (N=330)
Age at diagnosis		
n	503	289
Median (Q1, Q3)	67.0 (60.0, 72.0)	67.0 (59.0, 73.0)
Range	29.0-84.0	35.0-89.0
Disease length at inclusion		
n	503	289
Median (Q1, Q3)	4.0 (1.5, 8.0)	4.0 (2.0, 7.0)
Range	0.0-36.0	0.0-33.0
Hoehn & Yahr		
n	514	295
Median (Q1, Q3)	2.0 (1.5, 3.0)	2.0 (1.5, 3.0)
Range	0.0-5.0	0.0-5.0
CISI-PD		
n	518	301
Median (Q1, Q3)	5.0 (3.0, 8.0)	5.0 (2.0, 7.0)
Range	0.0-21.0	0.0-20.0
PDQ-8		
n	518	299
Median (Q1, Q3)	6.0 (2.0, 10.0)	7.0 (3.0, 11.0)
Range	0.0-25.0	0.0-21.0

Data retrieved from the Swedish Parkinson Registry. CISI-PD: Clinical Impression of Severity Index -Parkinson's Disease, summary score; PDQ-8: Parkinson's Disease Questionnaire - 8, summary score.

### Table 3: Identified haplotypes in the PLPP4 locus

Locus SNPs Haplotype MAF MAF KB OR <sup>a</sup> 95%CI <sup>a</sup> P-value (N) Pat. Ctrls	OR <sup>b</sup>	95%CI <sup>b</sup>	P-value <sup>b</sup>	OR <sup>c</sup>	95%CI	P-value <sup>c</sup>	SNPs
H1 8 GACGGGGG 0.901 0.911 41.334 1.00 Ref. 3.00E-0	1.00	Ref.	3.20E-01	1.00	Ref.	3.00E-01	rs2420703 rs71484626 rs2420706 rs2420707 rs2901235 rs12571802 rs2901237 rs17100130
H1 8 AGAAAAAA 0.013 0.012 41.334 1.19 0.92-1.5 1.73E-0	l 1.19	0.92-1.5	8.20E-01	1.20	0.92-1.6	1.70E-01	rs2420703 rs71484626 rs2420706 rs2420707 rs2901235 rs12571802 rs2901237 rs17100130
H1 8 GGCGAGGG 0.076 0.065 41.334 1.09 0.60-2.0 8.10E-0	1.08	0.59-2.0	1.80E-01	1.07	0.58-1.9	8.60E-01	rs2420703 rs71484626 rs2420706 rs2420707 rs2901235 rs12571802 rs2901237 rs17100130
H2 2 GG 0.750 0.763 10.817 1.00 Ref. 3.28E-0	1.00	Ref.	3.16E-01	1.00	Ref.	4.39E-01	rs7068076 rs36108282
H2 2 AA 0.071 0.047 10.817 1.56 1.17-2.06 1.48E-0	3 1.54	1.16-2.04	2.31E-03	1.48	1.11-1.97	5.57E-03	rs7068076 rs36108282
H2 2 AG 0.178 0.188 10.817 0.97 0.82-1.14 4.15E-0	l 0.97	0.82-1.15	4.74E-01	0.96	0.81-1.14	4.23E-01	rs7068076 rs36108282
H3 3 GAG 0.448 0.450 7.153 1.00 Ref. 9.07E-0	1.00	Ref.	9.93E-01	1.00	Ref.	8.53E-01	rs4595466 rs2244544 rs77772193
H3 3 GGG 0.129 0.094 7.153 1.34 1.08-1.65 1.30E-0	3 1.33	1.07-1.65	1.36E-03	1.31	1.06-1.63	1.99E-03	rs4595466 rs2244544 rs77772193
H3 3 GGA 0.082 0.070 7.153 1.19 0.92-1.53 1.56E-0	l 1.17	0.91-1.51	1.83E-01	1.14	0.89-1.48	2.38E-01	rs4595466 rs2244544 rs77772193
H3 3 AGG 0.341 0.386 7.153 0.88 0.76-1.02 4.12E-0	3 0.88	0.76-1.01	3.30E-03	0.87	0.75-1.01	3.10E-03	rs4595466 rs2244544 rs77772193
H4 2 CA 0.492 0.512 5.468 1.00 Ref. 2.35E-0	1.00	Ref.	2.71E-01	1.00	Ref.	3.12E-01	rs60288721 rs1536389
H4 2 CG 0.432 0.415 5.468 1.08 0.95-1.24 2.83E-0	1.07	0.94-1.23	3.44E-01	1.07	0.94-1.22	3.65E-01	rs60288721 rs1536389
H4 2 AA 0.075 0.073 5.468 1.07 0.83-1.38 8.08E-0	1.08	0.83-1.39	7.49E-01	1.06	0.82-1.37	8.24E-01	rs60288721 rs1536389
H5 2 CA 0.482 0.494 5.908 1.00 Ref. 4.72E-0	1.00	Ref.	5.06E-01	1.00	Ref.	5.46E-01	rs11199378 rs12768425
H5 2 AC 0.491 0.477 5.908 1.06 0.93-1.06 3.82E-0	1.05	0.92-1.20	4.33E-01	1.04	0.92-1.19	5.04E-01	rs11199378 rs12768425
H5 2 AA 0.011 0.009 5.908 1.21 0.63-2.32 6.15E-0	1.19	0.61-2.30	6.51E-01	1.26	0.65-2.45	5.28E-01	rs11199378 rs12768425
H5 2 CC 0.016 0.020 5.908 0.81 0.50-1.32 3.34E-0	0.84	0.51-1.39	4.30E-01	0.86	0.52-1.41	4.75E-01	rs11199378 rs12768425
H6 5 GGAGA 0.408 0.359 41.913 1.00 Ref. 2.03E-0	3 1.00	Ref.	1.59E-03	1.00	Ref.	1.59E-03	rs978854 rs7910507 rs10886711 rs11199417 rs10886717
H6 5 GAGGA 0.039 0.028 41.913 1.17 0.82-1.68 1.03E-0	1.19	0.83-1.70	8.96E-02	1.15	0.80-1.65	1.29E-01	rs978854 rs7910507 rs10886711 rs11199417 rs10886717
H6 5 AGGAA 0.209 0.189 41.913 0.97 0.81-1.16 1.16E-0	0.98	0.82-1.17	9.48E-02	0.97	0.81-1.16	1.08E-01	rs978854 rs7910507 rs10886711 rs11199417 rs10886717
H6 5 GAGGG 0.050 0.050 41.913 0.91 0.67-1.24 8.35E-0	0.90	0.66-1.24	8.67E-01	0.91	0.66-1.25	8.08E-01	rs978854 rs7910507 rs10886711 rs11199417 rs10886717
H6 5 GGGGA 0.242 0.302 41.913 0.70 0.60-0.83 4.67E-0	5 0.70	0.59-0.82	3.28E-05	0.69	0.59-0.82	2.54E-05	rs978854 rs7910507 rs10886711 rs11199417 rs10886717
H6 5 AGGGA 0.045 0.063 41.913 0.59 0.44-0.81 7.14E-0	3 0.59	0.43-0.81	7.29E-03	0.97	0.81-1.16	8.92E-03	rs978854 rs7910507 rs10886711 rs11199417 rs10886717
H7 3 GGG 0.439 0.408 2.751 1.00 Ref. 6.06E-0	2 1.00	Ref.	9.14E-02	1.00	Ref.	7.22E-02	rs75318356 rs7912073 rs11199429
H7 3 GGA 0.403 0.402 2.751 0.93 0.81-1.07 9.55E-0	0.94	0.82-1.09	8.91E-01	0.93	0.81-1.08	9.83E-01	rs75318356 rs7912073 rs11199429
H7 3 AAA 0.115 0.123 2.751 0.87 0.70-1.07 3.95E-0	0.88	0.71-1.10	4.86E-01	0.87	0.70-1.08	4.20E-01	rs75318356 rs7912073 rs11199429
H7 3 GAA 0.044 0.065 2.751 0.63 0.47-0.85 4.83E-0	3 0.63	0.46-0.85	5.00E-03	0.64	0.47-0.87	7.71E-03	rs75318356 rs7912073 rs11199429
H8 2 GG 0.663 0.683 0.417 1.00 Ref. 1.85E-0	1.00	Ref.	2.16E-01	1.00	Ref.	2.09E-01	rs9943454 rs41287958
H8 2 AG 0.259 0.250 0.417 1.07 0.92-1.24 5.11E-0	1.07	0.92-1.24	5.14E-01	1.07	0.92-1.25	4.71E-01	rs9943454 rs41287958
H8 2 GA 0.078 0.067 0.417 1.21 0.93-1.56 1.95E-0	1.18	0.91-1.53	2.54E-01	1.17	0.90-1.52	2.91E-01	rs9943454 rs41287958
H9 2 AG 0.523 0.512 6.032 1.00 Ref. 5.01E-0	1.00	Ref.	5.12E-01	1.00	Ref.	5.39E-01	rs2420779 rs12415215
H9 2 CG 0.428 0.436 6.032 0.96 0.84-1.10 6.20E-0	0.96	0.84-1.10	6.28E-01	0.96	0.84-1.10	6.18E-01	rs2420779 rs12415215
H9 2 AA 0.050 0.052 6.032 0.92 0.69-1.24 6.90E-0	0.93	0.69-1.25	6.97E-01	0.94	0.70-1.28	7.91E-01	rs2420779 rs12415215
H10 3 AGA 0.291 0.293 12.005 1.00 Ref. 9.01E-0	1.00	Ref.	9.89E-01	1.00	Ref.	9.86E-01	rs10886725 rs7068008 rs4752444
H10 3 AGG 0.273 0.248 12.005 1.11 0.93-1.41 9.20E-0	2 1.11	0.93-1.32	7.26E-02	1.11	0.93-1.32	6.41E-02	rs10886725 rs7068008 rs4752444
H10 3 AAG 0.280 0.280 12.005 1.01 0.85-1.20 9.95E-0	l 0.99	0.84-1.18	8.87E-01	1.00	0.84-1.19	9.09E-01	rs10886725 rs7068008 rs4752444
H10 3 GAG 0.156 0.178 12.005 0.89 0.73-1.08 7.51E-0	2 0.87	0.72-10.6	5.85E-02	0.87	0.71-1.06	4.66E-02	rs10886725 rs7068008 rs4752444
H11 3 AGG 0.523 0.533 0.866 1.00 Ref. 5.42E-0	1.00	Ref.	5.91E-01	1.00	Ref.	6.15E-01	rs2420768 rs7914572 rs11594222
H11 3 GAG 0.249 0.235 0.866 1.07 0.92-1.26 3.07E-0		0.92-1.26	2.75E-01	1.12	0.91-1.38	2.62E-01	rs2420768 rs7914572 rs11594222
H11 3 GGG 0.123 0.111 0.866 1.12 0.91-1.38 2.72E-0	l 1.11	0.90-1.37	3.12E-01	1.08	0.92-1.26	2.64E-01	rs2420768 rs7914572 rs11594222
H11 3 GGA 0.104 0.121 0.866 0.89 0.72-1.09 1.21E-0	0.88	0.71-1.08	9.46E-02	0.86	0.70-1.06	6.28E-02	rs2420768 rs7914572 rs11594222
H12 3 CGA 0.361 0.363 18.819 1.00 Ref. 8.97E-0	1.00	Ref.	9.90E-01	1.00	Ref.	9.12E-01	rs10458766 rs11199483 rs12570141
H12 3 AAA 0.280 0.255 18.819 1.10 0.93-1.30 8.82E-0	2 1.08	0.92-1.28	1.35E-01	1.09	0.92-1.29	1.43E-01	rs10458766 rs11199483 rs12570141
H12 3 AGA 0.272 0.278 18.819 0.98 0.83-1.15 6.53E-0	0.98	0.83-1.15	7.19E-01	0.98	0.83-1.16	6.62E-01	rs10458766 rs11199483 rs12570141
H12 3 AGG 0.084 0.100 18.819 0.84 0.66-1.07 9.04E-0	2 0.83	0.66-1.06	8.19E-02	0.87	0.68-1.10	1.55E-01	rs10458766 rs11199483 rs12570141

Identified haplotypes from genotyped variants in  $PLPP4 \pm 100$  kb upstream or downstream. A total of 45 haplotypes were identified in 12 haplotype blocks.

<sup>a</sup> Unadjusted logistic regression analyses
<sup>b</sup> Logistic regression analyses adjusted for age, sex and PC1-5
<sup>c</sup> Logistic regression analyses adjusted for age, sex, PC1-5 and tobacco use
Haplotypes indicating a significant association with PD at a corrected p-value threshold of 0.003 are marked in bold.

### Table 4: Number of variants in PLPP4 tested through SKAT and the results statistics at MAF threshold 1% and 5% in the genotyped data vs the imputed

	MAF < 1%		MAF < 5%	
	No. Variants	p-value	No. Variants	p-value
Genotyped data				
All variants	1	NA	16	0.002
Coding variants	0	NA	0	NA
Imputed data				
All variants	402	0.109	628	0.005
Coding variants	1	0.562	1	0.562

Analyses were adjusted for age at inclusion, sex and PC1-5

Results significant at Bonferroni correction are highlighted in bold


# Figures

Risk factor	OR	
Coffee age <41 years • Nothing • 1-2 cups/day • 3-5 cups/day • >5 cups/day	1.00 0.82 0.71 0.52	
Coffee age 41-64 years • Nothing • 1-2 cups/day • 3-5 cups/day • >5 cups/day	1.00 0.88 0.62 0.43	
Coffee age >64 years • Nothing • 1-2 cups/day • 3-5 cups/day • >5 cups/day	1.00 0.74 0.49 0.36	
Snus • Ever vs. never	0.53	·•
Tobacco • Ever vs. never	0.72	·•
Smoking • Current vs. never • Ever vs. never • Past vs. never • Pack-years (Ever-smokers)	0.76 0.82 0.83 0.99	
Well-water	1.02	
BMI • Age 20 • Highest	1.05 1.01	. <b>.</b> .
Farming	1.09	••
Head trauma • Loss of consciousness	1.30 0.76	
PD family history • 1st degree • Any relative	1.31 2.00	
Pesticides	2.26	••
	0.10	
	0.10	0.50 1.0 2.0 10.0 Odds ratio (OR)

### Figure 1: Forest plot over the associations between risk factors and PD in MPBC.

Showing the adjusted OR and 95% CI. Number of individuals in each analysis is found in

Table S1.



### Figure 2: Forest plot over the associations between various variables and PD. Analyzed

variables were obtained from questions regarding exposure/use within the past year prior to

study inclusion. The plot shows OR and 95% CI adjusted by age at inclusion and sex.

Number of individuals in each analysis is found in Table S2.







Figure 3: Manhattan plot showing the result from PD GWA analysis. A total of

5,445,841 SNPs (MAF >5%) were tested for 929 PD patients vs 935 controls. The y-axis represents the negative log (two-sided p-values) for association of variants with PD and the x-axis represent the genomic position on genome build GRCh37. The horizontal dashed line indicates the genome-wide significance level (p=5E-08).



**Figure 4: LocusZoom plot for PD GWAS PLPP4 loci.** Imputed and genotyped variants passing QC in the *PLPP4* gene +/- 100 kb (10:122116466-122449376) mapped to genome build GRCh37. The only coding gene in the region is *PLPP4*, other include pseudogenes (AC073587.1) and long non-coding RNA (LINC01561, AC023282.1, WDR11-AS1). The variant with lowest p-value (index) is indicated as a purple diamond. Marker colors indicate the strength of LD as r^2 between the index variant and other variants in the 1000 Genomes EUR population.






Figure 5: Genetic risk score (GRS) quartiles vs disease status (A) and age at diagnosis (AAD) (B and C). A: Odds ratio of PD status per risk quartile of the Z-standardized GRS. B: Regression line for the association between the Z-standardized GRS and AAD. The line represents the parameter estimate and the shading the 95% CI of the regression model. The model was adjusted for sex, PD family history, and PC1-5. C: AAD and Z-standardized GRS for each study participant with the regression model in plot B fitted to the plot.